They demonstrated that combination treatment with infliximab and MTX significantly reduced C2C/PIICP ratios during the 54-week observation period in patients with early RA, and this decrease was correlated with changes in CRP, DAS28, radiographic progression, and patient function (HAQ). This evidence concerns the gene CRP and rheumatoid arthritis.